NCI OUTSTANDING INVESTIGATOR GRANT

继续发现新的和潜在的重要癌症 从动物和植物来源的化疗药物将形成急剧的 杰出研究者补助金（Outstanding Investigator Grant，OIG） 国家癌症研究所（NCI）。 为了提供 最好的选择，为最终的临床试验，其中非常重要的 苔藓抑素类、多拉司他汀类、泮他汀类和叶下珠菌素类 （phyllanthoside）最近在我们研究所的合作中发现， 与NCI的研究计划，将加大努力， 发现每个系列的其他成员，并使他们 结构解析 虽然这项重要的研究正在进行中， 长期研究，针对分离，表征和结构 海洋生物中潜在抗癌新药研究进展 动物和植物将继续。 提供财政支助 OIG计划将用于分离和表征此类新癌症 从证实的海洋生物活性提取物中提取的化疗药物 无脊椎动物和脊椎动物以及海洋陆地植物。 的 主要重点将是海洋动植物物种产量 提取物具有突出的确认活性水平（T/C >150）， NCI的鼠P-388淋巴细胞白血病，NCI的人类癌细胞系统， 后来又部分使用了新的微生物和生化类型 目前正在评估预选方法。 只有那些 最大限度地保证在潜在的临床水平上生产新药， 将作为OIG研究的一部分进行研究。 其他此类线索 将在其他财政支持下优先考虑， 可能在那个时候可用。 因为花了30年时间建造 为这项抗癌药物发现研究奠定了基础， 已经发现了非常有前途的动植物物种 并将沿着新开发的销售线索， 具有潜在用途的独特的可再生物质的生产性产出 结构 OIOG提出的计划将对 NCI在选择新的抗癌候选药物和加速其 向临床试验发展。 总的来说，OIG计划 将集中精力发现和快速发展新的 国家癌症研究所项目的抗癌和艾滋病药物 旨在改善人类癌症和艾滋病的治疗。

Continued discovery of novel and potentially important cancer chemotherapeutic drugs from animal and plant sources will form the sharply focused objective of the overall Outstanding Investigator Grant (OIG) program with the National Cancer Institute (NCI). In order to provide the best choices for eventual clinical trial among the very important bryostatins, dolastatins, pancratistatin and the phyllanthostatins (phyllanthoside) recently discovered in our institute's collaborative research programs with the NCI, increased efforts will be devoted to uncovering additional members of each series and subjecting them to structural elucidation. While this important research is in progress a long-term study directed at the isolation, characterization and structural elucidation of new and potentially useful anticancer drugs from marine animals and plants will be continued. Financial support provided by the OIG program would be used to isolate and characterize such new cancer chemotherapeutic drugs from confirmed active extracts of marine invertebrates and vertebrates as well as marine terrestrial plants. The principal focus would be upon marine animal and plant species yielding extracts with an outstanding level of confirmed activity (T/C >150) in the NCI's murine P-388 lymphocytic leukemia, the NCI human caner cell systems, and later using, in part, new micro-organism and biochemical type preselection methods now under evaluation. Only those species that give maximum promise of yielding new drugs at a potential clinical level of interest will be pursued as part of the OIG research. Other such leads of a lesser priority will be pursued with any other financial support that might be available at that time. Because of 30 years spent building the foundation for this anticancer drug discovery research, a good number of exceedingly promising animal and plant species have already been uncovered and will be used along with newly developed leads to maintain a very productive output of potentially useful antineoplastic substances of unique structure. The OIOG program proposed will be of great assistance to the NCI in selecting new anticancer drug candidates and speeding their development toward clinical trial. In summary, the overall OIG program will be sharply focused on the discovery and very rapid development of new anticancer and HIV drugs for the national Cancer Institute's programs directed at improving human cancer and AIDS treatment.